Targeting PI3K-AKT Pathway for Cancer Therapy

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 2, 2003, Pages 205-228

  Lu, Yiling ^a   Wang, Hongwei ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; EVEROLIMUS; FK 506 BINDING PROTEIN; GELDANAMYCIN; IMATINIB; IMC C 225; MACROLIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; STAUROSPORINE; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; WORTMANNIN; ZD 1859;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CHROMOSOME 10; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COWDEN SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GRAFT REJECTION; HAMARTOMA; HEAD AND NECK CANCER; HUMAN; LEUKEMOGENESIS; LUNG CANCER; LUNG SMALL CELL CANCER; MULTIPLE CANCER; OVARY CANCER; PATIENT CARE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 0345276609     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science, 296: 1655-1657, 2002.
2. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol, 17: 615-675, 2001.
3. Vanhaesebroeck B and Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res, 253: 239-254, 1999.
4. Berrie CP. Phosphoinositide 3-kinase inhibition in cancer treatment. Expert Opin Investig Drugs, 10: 1085-1098, 2001.
5. Wymann MP and Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta, 1436: 127-150, 1998.
6. Vanhaesebroeck B, Leevers SJ, Panayotou G, et al. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci, 22: 267-272, 1997.
7. Yu J, Wjasow C, Backer JM. Regulation of the p85/p110alpha phosphatidylinositol 3′-kinase. Distinct roles for the N-terminal and C-terminal SH2 domains. J Biol Chem, 273: 30199-30203, 1998.
8. Cuevas BD, Lu Y, Mao M, et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem, 276: 27455-27461, 2001.
9. Chan TO, Rodeck U, Chan AM, et al. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell, 1: 181-191, 2002.
10. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res, 61: 7426-7429, 2001.
11. Stoyanov B, Volinia S, Hanck T, et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science, 269: 690-693, 1995.
12. Lopez-Ilasaca M, Crespo P, Pellici PG, et al. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI3-kinase gamma. Science, 275: 394-397, 1997.
13. Stephens LR, Eguinoa A, Erdjument-Bromage H, et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell, 89: 105-114, 1997.
14. Condliffe AM and Hawkins PT. Cell biology. Moving in mysterious ways. Nature, 404: 135, 137, 2000.
15. Sasaki T, Suzuki A, Sasaki J, et al. Phosphoinositide 3-kinases in immunity: lessons from knockout mice. J Biochem (Tokyo), 131: 495-501, 2002.
16. Panaretou C, Domin J, Cockcroft S, et al. Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150. Ptdins 3-kinase complex. J Biol Chem, 272: 2477-2485, 1997.
17. Bi L, Okabe I, Bernard DJ, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem, 274: 10963-10968, 1999.
18. Suzuki H, Terauchi Y, Fujiwara M, et al. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science, 283: 390-392, 1999.
19. Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science, 283: 393-397, 1999.
20. Roche S, Downward J, Raynal P, et al. A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction. Mol Cell Biol, 18: 7119-7129, 1998.
21. Roche S, Koegl M, Barone MV, et al. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol Cell Biol, 15: 1162-1109, 1995.
22. Vanhaesebroeck B, Jones GE, Allen WE, et al. Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol, 1: 69-71, 1999.
23. Li DM and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res, 57: 2124-2129, 1997.
24. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275: 1943-1947, 1997.
25. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15: 356-362, 1997.
26. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 273: 13375-13378, 1998.
27. Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell, 99: 323-334, 1999.
28. Bonneau D and Longy M. Mutations of the human PTEN gene. Hum Mutat, 16: 109-122, 2000.
29. Koul D, Jasser SA, Lu Y, et al. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene, 21: 2357-2364, 2002.
30. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet, 7: 507-515, 1998.
31. Leslie NR, Gray A, Pass I, et al. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Biochem J, 346 Pt 3: 827-833, 2000.
32. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA, 95: 13513-13518, 1998.
33. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280: 1614-1617, 1998.
34. Freeman DJ, Li AG, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell, 3: 117-130, 2003.
35. Leslie NR and Downes CP. PTEN: The down side of PI 3-kinase signalling. Cell Signal, 14: 285-295, 2002.
36. Lu Y, Lin YZ, LaPushin R, et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene, 18: 7034-7045, 1999.
37. Yamada KM and Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci, 114: 2375-2382, 2001.
38. Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer, 91: 22-26, 2001.
39. Torres J and Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem, 276: 993-998, 2001.
40. Vazquez F, Ramaswamy S, Nakamura N, et al. W. R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol, 20: 5010-5018, 2000.
41. Adey NB, Huang L, Ormonde PA, et al. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res, 60:35-37, 2000.
42. Vazquez F, Grossman SR, Takahashi Y, et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem, 276: 48627-48630, 2001.
43. Vivanco I. and Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2: 489-501, 2002.
44. Alessi DR. Discovery of PDK1, one of the missing links in insulin signal transduction. Colworth Medal Lecture. Biochem Soc Trans, 29: 1-14, 2001.
45. Nicholson KM and Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal, 14: 381-395, 2002.
46. Hill MM and Hemmings BA. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther, 93: 243-251, 2002.
47. Maira SM, Galetic I, Brazil DP, et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science, 294: 374-380, 2001.
48. Laine J, Kunstle G, Obata T, et al. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell, 6: 395-407, 2000.
49. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA, 97: 3028-3033, 2000.
50. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868, 1999.
51. Dijkers PF, Medema RH, Lammers JW, et al. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol, 10: 1201-1204, 2000.
52. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI3k/Akt-dependent pathway. Embo J, 16: 6151-6161, 1997.
53. Pugazhenthi S, Nesterova A, Sable C, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem, 275: 10761-10766, 2000.
54. Du K and Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem, 273: 32377-32379, 1998.
55. Wang JM, Chao JR, Chen W, et al. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol, 19: 6195-6206, 1999.
56. Romashkova JA and Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401: 86-90, 1999.
57. Ozes ON, Mayo LD, Gustin JA, et al. D. B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401: 82-85, 1999.
58. Barkett M and Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene, 18: 6910-6924, 1999.
59. Lauder A, Castellanos A and Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of T cells and is required for PKB-mediated protection from apoptosis. Mol Cell Biol, 21: 5797-5805, 2001.
60. Datta SR, Dudek H, Tao X, et al, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
61. Datta SR, Brunet A and Greenberg ME. Cellular survival: a play in three Akts. Genes Dev, 13: 2905-2927, 1999.
62. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science, 282: 1318-1321, 1998.
63. Fujita E, Jinbo A, Matuzaki H, et al. Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochem Biophys Res Commun, 264: 550-555, 1999.
64. Kim AH, Khursigara G, Sun X, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol, 21: 893-901, 2001.
65. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 275: 90-94, 1997.
66. Mayo LD and Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA, 98: 11598-11603, 2001.
67. Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol, 3: 973-982, 2001.
68. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol, 3: 245-252, 2001.
69. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med, 8: 1136-1144, 2002.
70. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med, 8: 1145-1152, 2002.
71. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med, 8: 1153-1160, 2002.
72. Medema RH, Kops GJ, Bos JL, et al. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature, 404: 782-787, 2000.
73. Blume-Jensen P and Hunter T. Oncogenic kinase signalling. Nature, 411: 355-365, 2001.
74. Shtivelman E, Sussman J and Stokoe D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol, 12: 919-924, 2002.
75. Nave BT, Ouwens M, Withers DJ, et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J, 344 Pt 2: 427-431, 1999.
76. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res, 60: 3504-3513, 2000.
77. Brunn GJ, Williams J, Sabers C, et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. Embo J, 15: 5256-5267, 1996.
78. Chen J and Fang Y. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol, 64: 1071-1077, 2002.
79. Leevers SJ, Vanhaesebroeck B and Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol, 11: 219-225, 1999.
80. Schmelzle T and Hall MN. TOR, a central controller of cell growth. Cell, 103: 253-262, 2000.
81. Chan TO, Rittenhouse SE and Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem, 68:965-1014, 1999.
82. Mills GB, Lu Y, Fang X, et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol, 28: 125-141, 2001.
83. Hutchinson J, Jin J, Cardiff RD, et al. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol, 21: 2203-2212, 2001.
84. Klingler-Hoffmann M, Bukczynska P and Tiganis T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer, 105: 331-339, 2003.
85. Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science, 276: 1848-1850, 1997.
86. Klippel A, Escobedo MA, Wachowicz MS, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol, 18: 5699-5711, 1998.
87. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res, 57: 5221-5225, 1997.
88. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol, 8: 1169-1178, 1998.
89. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA, 96: 1563-1568, 1999.
90. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet, 21: 99-102, 1999.
91. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene, 19: 2739-2744, 2000.
92. Mills GB, Lu Y and Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA, 98: 10031-10033, 2001.
93. Barlund M, Monni O, Kononen J, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res, 60: 5340-5344, 2000.
94. Zheng Y, Bagrodia S, Cerione RA. Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J Biol Chem, 269: 18727-18730, 1994.
95. Zhang W, Sloan-Lancaster J, Kitchen J, et al. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell, 92: 83-92, 1998.
96. Bruyns E, Marie-Cardine A, Kirchgessner H, et al. B. T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane. J Exp Med, 188: 561-575, 1998.
97. Genot EM, Arrieumerlou C, Ku G, et al. The T-cell receptor regulates Akt (protein kinase B) via a pathway involving Rac1 and phosphatidylinositide 3-kinase. Mol Cell Biol, 20: 5469-5478, 2000.
98. Okkenhaug K and Rottapel R. Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction. J Biol Chem, 273: 21194-21202, 1998.
99. Gu H, Maeda H, Moon JJ, et al. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol, 20: 7109-7120, 2000.
100. Gadina M, Sudarshan C, Visconti R, et al. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J Biol Chem, 275: 26959-26966, 2000.
101. Sotsios Y and Ward SG. Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Immunol Rev, 177: 217-235, 2000.
102. Borlado LR, Redondo C, Alvarez B, et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J, 14: 895-903, 2000.
103. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of PTEN leads to defects in central and peripheral tolerance. Immunity, 14: 523-534, 2001.
104. Harada Y, Tokushima M, Matsumoto Y, et al. Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo. J Immunol, 166: 3797-3803, 2001.
105. Dhand R, Hara K, Hiles I, et al. PI 3-kinase: structural and functional analysis of intersubunit interactions. Embo J, 13: 511-521, 1994.
106. Jones RG, Parsons M, Bonnard M, et al. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med, 191: 1721-1734, 2000.
107. Ahmed NN, Franke TF, Bellacosa A, et al. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene, 8: 1957-1963, 1993.
108. Mende I, Malstrom S, Tsichlis PN, et al. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene, 20: 4419-4423, 2001.
109. Jucker M, Sudel K, Horn S, et al. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia, 16: 894-901, 2002.
110. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res, 61: 2194-2199, 2001.
111. Pekarsky Y, Hallas C and Croce CM. Molecular basis of mature T-cell leukemia. Jama, 286: 2308-2314, 2001.
112. Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA, 99: 14392-14397, 2002.
113. Pekarsky Y, Hallas C and Croce CM. Targeting mature T cell leukemia: new understanding of molecular pathways. Am J Pharmacogenomics, 3: 31-36, 2003.
114. Gold MR. Akt is TCL-ish: implications for B-cell lymphoma. Trends Immunol, 24: 104-108, 2003.
115. West KA, Sianna Castillo S and Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat, 5: 234-248, 2002.
116. Hu L, Hofmann J, Lu Y, et al. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res, 62: 1087-1092, 2002.
117. Liang K, Jin W, Knuefermann C, et al. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther, 2: 353-360, 2003.
118. Hu L, Zaloudek C, Mills GB, et al. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res, 6: 880-886, 2000.
119. Shawver LK, Slamon D and Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell, 1: 117-123, 2002.
120. Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol, 30: 12-20, 2003.
121. Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res, 62: 4132-4141, 2002.
122. Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol, 28: 56-66, 2001.
123. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci, 94: 15-21, 2003.
124. Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer, 8: 237-248, 2001.
125. Walker EH, Perisic O, Ried C, et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature, 402: 313-320, 1999.
126. Djordjevic S and Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci, 27: 426-432, 2002.
127. Whiteman DC, Zhou XP, Cummings MC, et al. Nuclear PTEN expression and clinico-pathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer, 99: 63-67, 2002.
128. Flynn P, Wongdagger M, Zavar M, et al. D. Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol 10: 1439-1442, 2000.
129. Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA, 97: 3207-3212, 2000.
130. Kozikowski AP, Sun H, Brognard J, et al. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc, 125: 1144-1145, 2003.
131. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific Inhibition of the Akt1 Pleckstrin Homology Domain by D-3-Deoxy-Phosphatidyl-myo-Inositol Analogues. Mol Cancer Ther, 2: 389-399, 2003.
132. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res, 7: 1758-1764, 2001.
133. Lu Y, Yu Q, Liu JH, et al. Src family protein tyrosine kinases alter the function of PTEN to regulate PI3K/AKT cascades. J Biol Chem. 2003 (Epub ahead of print).